Home › Funds › Samsara BioCapital, LLC › VTVT

Samsara BioCapital, LLC position in VTVT

VTV THERAPEUTICS INC · Health Care

Samsara BioCapital, LLC reported holding 354,730 shares of VTVT (VTV THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$10.9M, representing 1.04% of its reported portfolio and ranking #15 among its reported holdings. Samsara BioCapital, LLC has disclosed VTVT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)354.73K sh
Reported value held$10.94M
Portfolio Weight1.04%
First reportedQ3 2023
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Samsara BioCapital, LLC's VTVT position evolved

Samsara BioCapital, LLC first disclosed a stake in VTVT in Q3 2023 at 1,635,509 shares (US$782K). The position peaked in Q4 2025 at 298,496 shares, worth US$11.9M. Across 13 filings, Samsara BioCapital, LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 354,730 shares valued at US$10.9M — an increase of 56,234 shares quarter over quarter.. Notable position changes include a 97% trim in Q4 2023 (shares rose 105% over the following quarter), a 406% increase in Q1 2024 (shares fell 25% over the following quarter), a 81% increase in Q3 2025 (shares rose 71% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.64M $781.77K New
Q4 2023 40.89K $470.21K Reduce
Q1 2024 206.78K $4.87M Add
Q2 2024 206.78K $3.65M Hold
Q3 2024 206.78K $2.81M Hold
Q4 2024 206.78K $2.86M Hold
Q1 2025 206.78K $3.58M Hold
Q2 2025 206.78K $3.10M Hold
Q3 2025 374.46K $8.74M Add
Q4 2025 298.50K $11.94M Reduce
Q1 2026 298.50K $11.84M Hold
Q2 2026 298.50K $11.24M Hold
Q3 2026 354.73K $10.94M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VTVT and 13F data

VTVT (VTV THERAPEUTICS INC) is a Health Care company. 34 other funds we track also report a position in VTVT — the largest reported positions include Trails Edge Capital Partners, LP (US$2.4M), Aisling Capital Management LP (US$1.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VTVT

All VTVT fund holders →

FAQ

How long has Samsara BioCapital, LLC held VTVT?

Samsara BioCapital, LLC has disclosed VTVT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Samsara BioCapital, LLC's current position in VTVT?

As of Q3 2026, Samsara BioCapital, LLC holds 354.73K shares of VTVT (VTV THERAPEUTICS INC), valued at $10.94M, representing 1.04% of its reported portfolio and ranking #15.

Has Samsara BioCapital, LLC been buying or selling VTVT?

In the latest 13F filing (Q3 2026), Samsara BioCapital, LLC increased its position in VTVT. The position peaked in Q4 2025 at 298.50K shares.

Which other funds hold VTVT?

Other major institutional holders of VTVT include Trails Edge Capital Partners, LP, Aisling Capital Management LP, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.